Last reviewed · How we verify
galantamine HBr
At a glance
| Generic name | galantamine HBr |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment (PHASE2)
- Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans (PHASE1, PHASE2)
- Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia (PHASE4)
- Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease (EARLY_PHASE1)
- Masitinib in Patients With Mild Alzheimer's Disease (PHASE3)
- Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke (PHASE2, PHASE3)
- Vagal Stimulation in POTS (PHASE1)
- Effect of Galantamine on Inflammation and Cognition (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- galantamine HBr CI brief — competitive landscape report
- galantamine HBr updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI